TP53 and melanoma: Given the major role of the p53 tumour suppressor protein and its reported implication in MAPK-driven melanomas [30,31], the combined targeting of the MAPK and p53 signalling pathways has been highlighted as a promising therapeutic strategy for melanoma patients [7,32,33,34].